Adagene Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ADAG Nasdaq 2836 www.adagene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adagene Inc.

Adagene to Participate in Two Upcoming Investor Conferences - May 12th, 2026 6:30 am
Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer - Apr 20th, 2026 8:15 am
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types - Apr 17th, 2026 2:01 pm
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board - Apr 14th, 2026 5:00 am
Incyte (INCY) Is Up 6.2% After Positive Povorcitinib Data And New Oncology Collaboration - Has The Bull Case Changed? - Apr 4th, 2026 11:09 pm
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs - Apr 2nd, 2026 5:10 am
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Apr 2nd, 2026 5:01 am
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response - Apr 2nd, 2026 5:00 am
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update - Apr 1st, 2026 3:00 pm
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA - Mar 17th, 2026 2:35 pm
Adagene Spotlights ADG126 at Leerink, Teases New MSS Colorectal Cancer Data Update Soon - Mar 9th, 2026 6:48 pm
Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk - Feb 25th, 2026 3:25 pm
Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders - Feb 16th, 2026 5:48 am
Adagene Provides Business Update and 2026 Objectives - Jan 23rd, 2026 6:00 am
Penny Stocks To Watch In January 2026 - Jan 19th, 2026 5:05 am
3 Promising Penny Stocks With Market Caps Over $30M - Dec 19th, 2025 11:05 am
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug - Dec 17th, 2025 6:43 am
Sector Update: Health Care Stocks Retreat Late Afternoon - Dec 16th, 2025 2:00 pm
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126) - Dec 16th, 2025 5:00 am
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology - Nov 13th, 2025 5:00 am